This is obviously amazing news for metastatic lung cancer patients with this difficult-to-treat disease and in dire need for novel therapeutic options. It is likewise excellent news to us at MedSIR. We are very proud and elated to be currently running a trial in Spain called the AZENT trial, which is actively enrolling patients across nearly a dozen centers in Spain. The FLAURA results give us great hope that patients in the AZENT trial -which is looking at the role of osimertinib in first-line metastatic NSCLC patients who harbor both the EGFR mutation and the concomitant EGFR T790M mutation- will also achieve excellent benefit.
You can get more information at the following link.